CARsgen Therapeutics (OTCMKTS:CRTHF) Shares Up 14.7% – Still a Buy?

Shares of CARsgen Therapeutics Holdings Limited (OTCMKTS:CRTHF) shot up 14.7% on Tuesday . The stock traded as high as $2.00 and last traded at $2.00. 1,500 shares changed hands during mid-day trading, an increase of 36% from the average session volume of 1,100 shares. The stock had previously closed at $1.7444.

CARsgen Therapeutics Price Performance

The firm’s 50 day moving average is $1.74 and its two-hundred day moving average is $1.57.

CARsgen Therapeutics Company Profile

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; CT011, which is in Phase I clinical trial for patients with Glypican-3 positive IIIa hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL).